nefazodone has been researched along with Chronic Disease in 41 studies
nefazodone: may be useful as an opiate adjunct
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess effectiveness, tolerability, and safety of nefazodone as a prophylactic agent for chronic daily headache." | 9.09 | Nefazodone for chronic daily headache prophylaxis: an open-label study. ( Lake, AE; Saper, JR; Tepper, SJ, 2001) |
| "Outpatients with chronic forms of DSM-IV major depressive disorder (N = 681) were randomly assigned to 12 weeks of nefazodone, Cognitive Behavioral Analysis System of Psychotherapy (CBASP), or combined nefazodone/CBASP." | 5.10 | Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination. ( Arnow, BA; Borian, FE; Dunner, DL; Gelenberg, AJ; Hirschfeld, RM; Keller, MB; Kornstein, SG; Manber, R; Ninan, PT; Rush, AJ; Thase, ME; Trivedi, MH; Zajecka, J, 2002) |
| "681 patients with chronic major depressive disorder (DSM-IV criteria) participated in a multicenter study of 12 weeks of acute treatment with nefazodone (N = 226), CBASP (N = 228), or the combination (N = 227)." | 5.10 | Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. ( Borian, FE; Crits-Christoph, P; Keller, MB; Kornstein, SG; Manber, R; Ninan, PT; Rothbaum, BO; Rush, AJ; Thase, ME; Trivedi, MH; Zajecka, J, 2002) |
| "We randomly assigned 681 adults with a chronic nonpsychotic major depressive disorder to 12 weeks of outpatient treatment with nefazodone (maximal dose, 600 mg per day), the cognitive behavioral-analysis system of psychotherapy (16 to 20 sessions), or both." | 5.09 | A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. ( Arnow, B; Dunner, DL; Gelenberg, AJ; Keller, MB; Klein, DN; Markowitz, JC; McCullough, JP; Nemeroff, CB; Russell, JM; Thase, ME; Trivedi, MH; Zajecka, J, 2000) |
| "To assess effectiveness, tolerability, and safety of nefazodone as a prophylactic agent for chronic daily headache." | 5.09 | Nefazodone for chronic daily headache prophylaxis: an open-label study. ( Lake, AE; Saper, JR; Tepper, SJ, 2001) |
| "Nefazodone treatment led to a significant decrease in PTSD and depressive symptoms (p <." | 2.71 | The effect of nefazodone on subjective and objective sleep quality in posttraumatic stress disorder. ( Lenoci, M; Leykin, Y; Maglione, ML; Marmar, CR; Metzler, TJ; Neylan, TC; Rosenlicht, NZ; Schoenfeld, FB, 2003) |
| "Participants were 431 chronically depressed patients who received Cognitive Behavioral Analysis System of Psychotherapy (CBASP), alone (N=214) or in combination with nefazodone (N=217), as part of a randomized chronic depression study (Keller et al." | 2.71 | Patient's therapeutic skill acquisition and response to psychotherapy, alone or in combination with medication. ( Arnow, B; Blalock, JA; Blasey, C; Keller, MB; Klein, DN; Manber, R; Markowitz, JC; McCullough, JP; Riso, LP; Rothbaum, B; Rush, AJ; Thase, ME; Vivian, D, 2003) |
| "Maintenance treatment to prevent recurrences is recommended for chronic forms of major depressive disorder (MDD), but few studies have examined maintenance efficacy of antidepressants with chronic MDD." | 2.71 | Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression. ( Arnow, B; Banks, P; Borian, FE; Dunner, DL; Gelenberg, AJ; Hirschfeld, RM; Howland, R; Keitner, GI; Keller, MB; Klein, DN; Kocsis, JH; Kornstein, SG; Manber, R; Markowitz, JC; Miller, I; Munsaka, M; Rothbaum, B; Rush, AJ; Russell, JM; Thase, ME; Trivedi, MH; Zajecka, J, 2003) |
| "Major depressive disorder is associated with considerable morbidity, disability, and risk for suicide." | 2.71 | Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. ( Dunner, DL; Heim, CM; Keitner, G; Keller, MB; Klein, DN; Kornstein, S; McCullough, JP; Nemeroff, CB; Ninan, PT; Rothbaum, BO; Rush, AJ; Schatzberg, AF; Thase, ME; Weiss, PM, 2003) |
| " The dosage of nefazodone was 100 to 600 mg/d; CBASP was provided twice weekly during weeks 1 through 4 and weekly thereafter." | 2.71 | Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not. ( Arnow, BA; Banks, PL; Blalock, JA; Borian, FE; Howland, R; Keller, MB; Klein, DN; Kocsis, JH; Kornstein, SG; Manber, R; Markowitz, JC; Miller, I; Ninan, PT; Rothbaum, BO; Rush, AJ; Schatzberg, AF; Thase, ME; Trivedi, MH, 2005) |
| "Patients with chronic forms of major depressive disorder were randomized to 12 weeks of nefazodone, Cognitive Behavioral Analysis System of Psychotherapy (CBASP), or combined nefazodone/CBASP." | 2.70 | Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. ( Borian, FE; Crits-Christoph, P; Dunner, DL; Hirschfeld, RM; Keitner, G; Keller, MB; Klein, DN; Koran, LM; Kornstein, SG; Markowitz, JC; Miller, I; Nemeroff, CB; Ninan, PT; Rush, AJ; Schatzberg, AF; Thase, ME; Trivedi, MH, 2002) |
| "Continuous and categorical insomnia outcomes, derived from standard clinician- and self-rated assessments, were compared." | 2.70 | Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depression. ( Borian, FE; Dunner, DL; Friedman, ES; Keller, MB; Klein, DN; Kornstein, SG; Manber, R; Markowitz, JC; Ninan, PT; Rush, AJ; Schatzberg, AF; Thase, ME; Trivedi, MH, 2002) |
| "Nefazodone treatment was well tolerated by this patient population, with only four patients discontinuing because of adverse effects." | 2.69 | Nefazodone treatment for chronic posttraumatic stress disorder: an open trial. ( Davis, LL; Kramer, GL; Murray, J; Nugent, AL; Petty, F, 2000) |
| "Posttraumatic stress disorder (PTSD) is a highly prevalent and often chronic disorder among combat veterans, persisting in as many as 15% of Vietnam veterans for at least 20 years." | 2.69 | Nefazodone in patients with treatment-refractory posttraumatic stress disorder. ( Chentsova-Dutton, YE; Ellenor, GL; Gillin, JC; Kline, NA; Kodsi, AB; Smith-Vaniz, A; Zisook, S, 2000) |
| "Nefazodone was well tolerated and no significant changes in sexual function were reported." | 1.31 | Three- to four-year follow-up to an open trial of nefazodone for combat-related posttraumatic stress disorder. ( Beckham, JC; Davidson, JR; Feldman, ME; Hertzberg, MA; Moore, SD, 2002) |
| "Nefazodone was associated with statistically significant improvement in mean scores on all six rating scales used to assess change from baseline in PTSD symptoms." | 1.30 | Treatment of posttraumatic stress disorder with nefazodone. ( Connor, KM; Davidson, JR; Malik, ML; Weisler, RH, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (9.76) | 18.2507 |
| 2000's | 34 (82.93) | 29.6817 |
| 2010's | 3 (7.32) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Steidtmann, D | 1 |
| Manber, R | 14 |
| Blasey, C | 3 |
| Markowitz, JC | 13 |
| Klein, DN | 16 |
| Rothbaum, BO | 6 |
| Thase, ME | 18 |
| Kocsis, JH | 9 |
| Arnow, BA | 7 |
| Kraemer, HC | 1 |
| Trivedi, MH | 12 |
| Rush, AJ | 15 |
| Gelenberg, AJ | 5 |
| Keller, ME | 1 |
| Leon, AC | 1 |
| Arnow, B | 6 |
| Maddux, RE | 1 |
| Riso, LP | 2 |
| Blalock, JA | 3 |
| Keitner, GI | 3 |
| Denton, WH | 1 |
| Carmody, TJ | 2 |
| Keller, MB | 14 |
| Stulz, N | 1 |
| Crits-Christoph, P | 3 |
| Zajecka, J | 5 |
| Dunner, DL | 11 |
| Hirschfeld, RM | 3 |
| Kornstein, SG | 8 |
| Ninan, PT | 6 |
| Borian, FE | 9 |
| Hertzberg, MA | 1 |
| Feldman, ME | 1 |
| Beckham, JC | 1 |
| Moore, SD | 1 |
| Davidson, JR | 2 |
| Amow, B | 1 |
| Klein, D | 1 |
| Korenstein, SG | 1 |
| Munsaka, M | 2 |
| Keller, B | 1 |
| Neylan, TC | 1 |
| Lenoci, M | 1 |
| Maglione, ML | 1 |
| Rosenlicht, NZ | 1 |
| Leykin, Y | 1 |
| Metzler, TJ | 1 |
| Schoenfeld, FB | 1 |
| Marmar, CR | 1 |
| Wynchank, D | 1 |
| Berk, M | 1 |
| Vivian, D | 1 |
| McCullough, JP | 3 |
| Rothbaum, B | 2 |
| Howland, R | 2 |
| Russell, JM | 3 |
| Miller, I | 3 |
| Banks, P | 1 |
| Nemeroff, CB | 4 |
| Heim, CM | 1 |
| Schatzberg, AF | 5 |
| Weiss, PM | 1 |
| Kornstein, S | 1 |
| Keitner, G | 3 |
| Koran, LM | 2 |
| Ibrahim, HM | 1 |
| Fawcett, J | 1 |
| Jody, DN | 1 |
| Banks, PL | 1 |
| Constantino, MJ | 1 |
| Anton, SF | 1 |
| Robinson, DS | 1 |
| Roberts, DL | 1 |
| Kensler, TT | 1 |
| English, PA | 1 |
| Archibald, DG | 1 |
| Weisler, RH | 1 |
| Malik, ML | 1 |
| Connor, KM | 1 |
| Mellman, TA | 1 |
| David, D | 1 |
| Barza, L | 1 |
| Brotto, LA | 1 |
| Hanson, LA | 1 |
| Gorzalka, BB | 1 |
| Davis, LL | 1 |
| Nugent, AL | 1 |
| Murray, J | 1 |
| Kramer, GL | 1 |
| Petty, F | 1 |
| Faber, RA | 1 |
| Benzick, JM | 1 |
| Scott, J | 1 |
| Zisook, S | 1 |
| Chentsova-Dutton, YE | 1 |
| Smith-Vaniz, A | 1 |
| Kline, NA | 1 |
| Ellenor, GL | 1 |
| Kodsi, AB | 1 |
| Gillin, JC | 1 |
| Baty, P | 1 |
| Rubin, RT | 1 |
| Umanoff, DF | 1 |
| Duncan, BL | 1 |
| Miller, SD | 1 |
| Veijola, JM | 1 |
| Saper, JR | 1 |
| Lake, AE | 1 |
| Tepper, SJ | 1 |
| Prather, MR | 1 |
| Laird, LK | 2 |
| Wright, CW | 1 |
| Bailey, L | 1 |
| Sussman, N | 1 |
| Seabolt, JL | 1 |
| Friedman, ES | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Partnership in Medication Management (PIMM): The Effects of One-on-one Medication Training on Medication Adherence in Patients With Mood Disorders[NCT02285608] | 166 participants (Anticipated) | Interventional | 2015-01-31 | Recruiting | |||
| Cognitive Behavioral Analysis System of Psychotherapy (CBASP) vs. Behavioral Activation (BA) in Persistently Depressed Treatment-resistant Inpatients: Efficacy, Moderators, and Mediators of Change[NCT04996433] | 396 participants (Anticipated) | Interventional | 2021-12-01 | Recruiting | |||
| Assessing the Emotional and Physiological Response of Adults to Completing a Self-report Scale on Exposure to Childhood Maltreatment - Online Component[NCT06152549] | 500 participants (Anticipated) | Observational | 2022-10-15 | Recruiting | |||
| Effectiveness of the Bonny Method of Guided Imagery and Music (GIM) in the Treatment of Depression: A Randomized Controlled Trial[NCT03917979] | 30 participants (Anticipated) | Interventional | 2019-03-20 | Recruiting | |||
| CBASP Augmentation for Treatment of Chronic Depression[NCT00057551] | Phase 4 | 491 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Hamilton Depression Scale (HAM-D)<8 and does not meet DSM-IV criteria for Major Depressive Disorder for 2 consecutive visits (NCT00057551)
Timeframe: 12 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| CBASP | 38.5 |
| Brief SP | 31.0 |
| Medication Only | 39.5 |
4 reviews available for nefazodone and Chronic Disease
| Article | Year |
|---|---|
New strategies for treating chronic depression.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Chronic Disease; Clinical Trials as | 2000 |
Acute and maintenance treatment of chronic depression.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Chronic Disease; Cognitive B | 2001 |
Clinical use of nefazodone in major depression: a 6-year perspective.
Topics: Age Factors; Antidepressive Agents, Second-Generation; Chronic Disease; Depressive Disorder; Hospita | 2002 |
Six-year perspectives on the safety and tolerability of nefazodone.
Topics: Age Factors; Antidepressive Agents, Second-Generation; Body Weight; Chronic Disease; Depressive Diso | 2002 |
26 trials available for nefazodone and Chronic Disease
| Article | Year |
|---|---|
Detecting critical decision points in psychotherapy and psychotherapy + medication for chronic depression.
Topics: Adult; Antidepressive Agents; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Thera | 2013 |
Patient preference as a moderator of outcome for chronic forms of major depressive disorder treated with nefazodone, cognitive behavioral analysis system of psychotherapy, or their combination.
Topics: Adult; Antidepressive Agents, Second-Generation; Chronic Disease; Cognitive Behavioral Therapy; Comb | 2009 |
Select comorbid personality disorders and the treatment of chronic depression with nefazodone, targeted psychotherapy, or their combination.
Topics: Adaptation, Psychological; Adult; Antidepressive Agents, Second-Generation; Chronic Disease; Cogniti | 2009 |
Dyadic discord at baseline is associated with lack of remission in the acute treatment of chronic depression.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Chronic Disease; Cognitive Behavi | 2010 |
Differential effects of treatments for chronic depression: a latent growth model reanalysis.
Topics: Adult; Antidepressive Agents, Second-Generation; Chronic Disease; Cognitive Behavioral Therapy; Comb | 2010 |
Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination.
Topics: Adult; Antidepressive Agents, Second-Generation; Attitude to Health; Chronic Disease; Cognitive Beha | 2002 |
The effects of psychotherapy, nefazodone, and their combination on subjective assessment of disturbed sleep in chronic depression.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Chronic Disease; Combined Modalit | 2003 |
The effect of nefazodone on subjective and objective sleep quality in posttraumatic stress disorder.
Topics: Antidepressive Agents, Second-Generation; Chronic Disease; Drug Administration Schedule; Humans; Mal | 2003 |
Efficacy of nefazodone in the treatment of neuroleptic induced extrapyramidal side effects: a double-blind randomised parallel group placebo-controlled trial.
Topics: Acute Disease; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Basal Ganglia Disease | 2003 |
Patient's therapeutic skill acquisition and response to psychotherapy, alone or in combination with medication.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Chronic Disease; Cognitive Behavi | 2003 |
Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression.
Topics: Acute Disease; Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Chronic Disease; C | 2003 |
Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Child; Child Abuse; Chronic Disea | 2003 |
Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Child; Child Abuse; Chronic Disea | 2003 |
Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Child; Child Abuse; Chronic Disea | 2003 |
Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Child; Child Abuse; Chronic Disea | 2003 |
Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Child; Child Abuse; Chronic Disea | 2003 |
Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Child; Child Abuse; Chronic Disea | 2003 |
Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Child; Child Abuse; Chronic Disea | 2003 |
Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Child; Child Abuse; Chronic Disea | 2003 |
Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Child; Child Abuse; Chronic Disea | 2003 |
Continuation treatment of chronic depression: a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Chronic Disease; Cognitive Behavi | 2003 |
Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Chronic Disease; Cognitive Behavi | 2005 |
Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not.
Topics: Adult; Antidepressive Agents, Second-Generation; Chronic Disease; Cognitive Behavioral Therapy; Cros | 2005 |
Dropouts versus completers among chronically depressed outpatients.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Anxiety Disorder | 2007 |
Long-term treatment of depression with nefazodone.
Topics: Antidepressive Agents; Chronic Disease; Depressive Disorder; Double-Blind Method; Humans; Imipramine | 1994 |
Nefazodone treatment and dream reports in chronic PTSD.
Topics: Aged; Antidepressive Agents, Second-Generation; Chronic Disease; Combat Disorders; Dreams; Female; H | 1999 |
Nefazodone treatment for chronic posttraumatic stress disorder: an open trial.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Chronic Disease; Combat Disorders; Female; Hu | 2000 |
A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Behavior Therapy; Chronic Disease; Cognitive Behavi | 2000 |
Nefazodone in patients with treatment-refractory posttraumatic stress disorder.
Topics: Ambulatory Care; Antidepressive Agents, Second-Generation; Chronic Disease; Circadian Rhythm; Combat | 2000 |
Does nefazadone alone, the cognitive behavioral-analysis system of psychotherapy, or the combination of both work best for patients with chronic depression?
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Behavior Therapy; Chronic Disease; Cognitive | 2000 |
Nefazodone for chronic daily headache prophylaxis: an open-label study.
Topics: Adolescent; Adult; Analgesics; Child; Chronic Disease; Female; Headache; Humans; Male; Medical Recor | 2001 |
Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination.
Topics: Adult; Antidepressive Agents, Second-Generation; Chronic Disease; Cognitive Behavioral Therapy; Comb | 2002 |
Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Chronic Disease; Cognitive Behav | 2002 |
Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Chronic Disease; Cognitive Behavioral Therapy; Comb | 2002 |
11 other studies available for nefazodone and Chronic Disease
| Article | Year |
|---|---|
Faster remission of chronic depression with combined psychotherapy and medication than with each therapy alone.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety Disorders; Chronic Disease; Cognitive Behavi | 2008 |
Three- to four-year follow-up to an open trial of nefazodone for combat-related posttraumatic stress disorder.
Topics: Adult; Anger; Antidepressive Agents, Second-Generation; Chronic Disease; Clinical Trials as Topic; C | 2002 |
Treatment of posttraumatic stress disorder with nefazodone.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Arousal; Chronic Disease; Dose-Re | 1998 |
Nefazodone attenuates the stress-induced facilitation of wet dog shaking behaviour but not the facilitation of sexual behaviour in female rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Chronic Disease; Corticosterone; Estradiol; Femal | 1999 |
Nafazodone-induced palinopsia.
Topics: Afterimage; Antidepressive Agents, Second-Generation; Chronic Disease; Depressive Disorder; Humans; | 2000 |
Treatment of chronic depression.
Topics: Antidepressive Agents, Second-Generation; Behavior Therapy; Chronic Disease; Cognitive Behavioral Th | 2000 |
Nefazodone, psychotherapy, and their combination for chronic depression.
Topics: Antidepressive Agents, Second-Generation; Chronic Disease; Combined Modality Therapy; Controlled Cli | 2000 |
Nefazodone, psychotherapy, and their combination for chronic depression.
Topics: Antidepressive Agents, Second-Generation; Chronic Disease; Combined Modality Therapy; Controlled Cli | 2000 |
Nefazodone, psychotherapy, and their combination for chronic depression.
Topics: Antidepressive Agents, Second-Generation; Chronic Disease; Combined Modality Therapy; Depressive Dis | 2000 |
Nefazodone, psychotherapy, and their combination for chronic depression.
Topics: Antidepressive Agents, Second-Generation; Chronic Disease; Combined Modality Therapy; Depressive Dis | 2000 |
Long-term treatment of recurrent and chronic depression.
Topics: Antidepressive Agents; Chronic Disease; Clinical Trials as Topic; Cognitive Behavioral Therapy; Comb | 2001 |